CSOP Hang Seng Biotech ETF (03174.HK) Falls 1.83% in Morning Trade, Turnover at HKD 2.8945 Million
NewTimeSpace News: As of September 10 at 10:13, CSOP Hang Seng Biotech ETF (03174.HK) fell 1.83%, with a latest price of HKD 3.652, an opening price of HKD 3.714, a high of HKD 3.714, a low of HKD 3.648, and an intraday amplitude of 1.77%. The ETF traded 788,800 shares, with a turnover of HKD 2.8945 Million and an average price of HKD 3.670. The premium rate is -0.11%, with a turnover rate of 0.31%. The current Net Asset Value (NAV) is HKD 3.724, with Assets Under Management (AUM) of HKD 949 Million, total outstanding shares of 255 Million, and a lot size of 100 shares.
CSOP Hang Seng Biotech ETF (03174.HK) closely tracks the Hang Seng Biotech Index. The index covers biotech companies listed in Hong Kong, focusing on pharmaceuticals, biotechnology, medical equipment, and other fields, capturing innovative growth opportunities in the Hong Kong biotech sector.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CSOP HS Biotech(03174.HK) +2.81%, Hengrui 9M net profit up 20.38%
- Chinese Innovative Drugs Set Record Share of ESMO Late-Breaking Abstracts; CSOP Hang Seng Biotech ETF (03174.HK) Rises 0.81% Intraday
- CSOP Hang Seng Biotech ETF (03174.HK) Rises 0.55% Intraday as Record 29 Chinese Studies Make ESMO Late-Breaker List
- HANSOH's ADC Licensing Deal with Roche Worth up to USD 15 Billion and a Record Share of Chinese Studies at ESMO LBA; CSOP Hang Seng Biotech ETF (03174.HK) Rises 2.09% Against the Trend on 20 October
- CSOP Hang Seng Biotech ETF (03174.HK) Rises 1.80% Intraday as Hansoh Signs Roche ADC Deal with US$400 Million Upfront